In a small cell therapy trial, 10 out of 12 people with type 1 diabetes no longer needed supplemental insulin, even a year after treatment.

As part of a clinical trial, the National Center for Tumor Diseases (NCT/UCC) Dresden is now offering patients with ...

Key Takeaways Atebimetinib combined with modified chemotherapy achieved a 94% six-month overall survival rate in first-line pancreatic cancer patients, surpassing the typical 67% with standard ...

Based on these encouraging phase 2a data, Immuneering, the company developing atebimetinib, has decided to increase the target enrollment in the first-line pancreatic cancer atebimetinib plus mGnP ...

Vaccines have had a major impact on the control of infectious disease, most recently by helping to combat the COVID-19 pandemic. Prophylactic cancer vaccines have prevented several malignancies by ...

IMUNON announces promising Phase 1 results for IMNN-101, a DNA plasmid vaccine demonstrating enhanced durability and potential advantages over mRNA vaccines. Quiver AI Summary IMUNON, Inc., a ...

A new kind of mRNA vaccine developed by researchers at the University of Pittsburgh and Penn State University could be cheaper to produce and offer a greater level of immunity across multiple ...

It has been over four years since the mRNA vaccines were introduced, and there have been no new safety concerns. Do not let fear-mongering persuade you. The vaccines are safe and could save your life.

Our functional understanding of the impact of EMT on cancer has been limited by the lack of effective tools to ablate tumor cells as they become mesenchymal. In a recent study published in Nature, ...